Clinical Trial Update: Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating reduced-intensity conditioning with busulfan and fludarabine, with or without antithymocyte globulin, followed by donor stem cell trans…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndromes
• Myeloproliferative Neoplasms
• Plasma Cell Neoplasms

Drugs mentioned

• Antithymocyte Globulin (anti-thymocyte globulin)
• BUSULFAN (Busulfan)
• Fludarabine (Fludarabine)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Chronic Myeloproliferative Disorders, Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2017-05-30